Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-PV-01 Combinations in Advanced Melanoma
NCT03597282Phase 1Terminated
- Sponsor
- BioNTech SE
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoVax in melanoma (7 arms), sponsored by BioNTech SE. Primary endpoint: Rate of adverse events and severe adverse events leading to treatment discontinuation. Started Oct 2018; status: terminated.
02
Drugs
NeoVax
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03597282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597282.